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Background: Detection of subclinical atherosclerosis improves risk prediction beyond 
cardiovascular risk factors (CVRF) and risk scores, but quantification of plaque burden 
may improve it further. Novel three-dimensional vascular ultrasound (3DVUS) provides 
accurate volumetric quantification of plaque burden. 
Objectives: To evaluate associations between 3DVUS-based plaque burden and CVRFs 
and explore potential added value over simple plaque detection.  
Methods: We included 3860 (92.2%) PESA (Progression of Early Subclinical 
Atherosclerosis) participants (age 45.8±4.3; 63% males). Bilateral carotid and femoral 
territories were explored by 3DVUS to determine the number of plaques and territories 
affected, and to quantify global plaque burden defined as the sum of all plaque volumes. 
Linear regression and proportional odds models were used to evaluate associations of 
plaque burden with CVRFs and estimated 10-year cardiovascular risk. 
Results: Plaque burden was higher in men (63.4 mm3 [23.8-144.8] vs 25.7 mm3 [11.5-
61.6] in women, p<0.001), in the femoral territory (64 mm3 [27.6-140.5] vs 23.1 mm3 
[9.9-48.7] in the carotid territory, p<0.001), and with increasing age (p<0.001). Age, sex, 
smoking, and dyslipidemia were more strongly associated with femoral than with carotid 
disease burden, whereas hypertension and diabetes showed no territorial differences. 
Plaque burden showed a direct association with estimated cardiovascular risk 
independently of the number of plaques or territories affected (p<0.01). 
Conclusions: 3DVUS quantifies higher plaque burden in men, in the femoral territory, 
and with increasing age during midlife. Plaque burden correlates strongly with CVRFs, 
especially at the femoral level, and reflects estimated cardiovascular risk more closely 
than plaque detection alone. 
KEY WORDS: subclinical atherosclerosis, three-dimensional ultrasound, plaque 
volume, carotid plaque, femoral plaque.  
 
CONDENSED ABSTRACT  
Subclinical atherosclerotic burden evaluation by novel 3D vascular ultrasound (3DVUS) 
may improve cardiovascular risk prediction beyond cardiovascular risk factors (CVRF). 
We evaluated carotid and femoral atherosclerotic burden by 3DVUS in 3860 
asymptomatic middle-aged participants of the PESA (Progression of Early Subclinical 
Atherosclerosis) study. 3DVUS quantifies higher plaque burden in men, in the femoral 
territory, and with increasing age (all p<0.001). Plaque burden correlates strongly with 
CVRFs, especially at the femoral level, and reflects estimated cardiovascular risk more 





2DVUS: 2 dimensional vascular ultrasound 
3DVUS: 3 dimensional vascular ultrasound 
ASCVD: Atherosclerotic cardiovascular disease 
BMI: Body mass index 
CACS: Coronary artery calcium score 
CV: Cardiovascular 
CVRF: Cardiovascular risk factors 
IMT: Intima-media thickness 
PB: plaque burden 




Detection of subclinical atherosclerosis improves cardiovascular risk stratification (1,2). 
A direct relationship between atherosclerotic lesions and conventional cardiovascular risk 
factors (CVRF) has been previously established, first with necropsy findings (3) and 
subsequently using different noninvasive imaging techniques. Coronary artery calcium 
score (CACS) and intima-media thickness (IMT) have been more widely explored in their 
relationship with CVRFs and cardiovascular risk than direct evaluation of atheromas. 
Nonetheless, increasing evidence reinforces the potential value for risk assessment of 
detecting atherosclerotic lesions (4-6) including multi-territorial evaluation since 
atherosclerosis is a systemic process (7,8). Two-dimensional vascular ultrasound 
(2DVUS) is well suited not only for detecting but also for grading the extent of 
atherosclerosis in different territories. However, methods for quantifying atherosclerotic 
plaque burden with 2DVUS have differed between studies and no consensus exists on 
which measurement should be used or which arterial territory is more suitable for 
cardiovascular risk prediction (9). 
Recently introduced semiautomated three-dimensional vascular ultrasound (3DVUS) has 
been proposed as a better method for quantifying peripheral atherosclerotic burden (10). 
Plaque volume may be a more comprehensive measure that incorporates disease presence 
and amount, and is thus more likely to reflect the cumulative effect of chronic CVRF 
exposure and individual susceptibility. However, 3DVUS has not been used to quantify 
multi-territorial plaque burden in large population studies, and the associations of plaque 
volume with CVRFs have not been explored. Our goals were to: 1) evaluate feasibility 
and reproducibility, and provide reference values of carotid and femoral plaque burden 
distribution by 3DVUS in asymptomatic middle-aged individuals; 2) determine the 
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relationship between CVRFs and plaque burden; and 3) explore the potential additive 
value of quantifying plaque volume versus plaque detection alone. 
METHODS 
The Progression of Early Subclinical Atherosclerosis (PESA-CNIC-Santander) study is 
an ongoing observational prospective cohort study aimed at characterizing early 
subclinical atherosclerotic burden and determinants of atherosclerosis presence and 
progression using different noninvasive image techniques. The study rationale and design 
have been reported in detail (11). Briefly, between June 2010 and February 2014, PESA 
enrolled 4184 volunteers between 40 and 54 years without prior cardiovascular disease 
who were employees at the Banco de Santander headquarters in Madrid (Spain). 
Participants completed a baseline visit that included 3DVUS in the carotid and femoral 
territories. In addition, the visit included clinical interviews, standardized lifestyle 
questionnaires, physical examination, fasting blood draw, urine sample collection, and 
12-lead ECG. Participants are being prospectively followed up with repeat visits at 3 and 
6 years. The study protocol has been approved by the Instituto de Salud Carlos III Ethics 
Committee and complies with the Declaration of Helsinki. All eligible participants have 
provided written informed consent. The definitions of CVRFs, including dyslipidemia, 
smoking, hypertension, diabetes, obesity, and family history of premature cardiovascular 
disease, are as reported previously (7). Cumulative smoking exposure was determined in 
terms of pack-years by multiplying the number of years smoked by the average number 
of packs per day. The ACC/AHA atherosclerotic cardiovascular disease (ASCVD) risk 
score was quantified, and classified according to 10-year risk as low (<5%), intermediate 





The 3DVUS examinations were performed with a Philips iU22 ultrasound system 
equipped with a VL13-5 3D volume-linear array transducer (Philips Health Care, 
Andover, MA, USA). Detailed 3DVUS acquisition and analysis methodology have been 
reported previously, together with experimental validation of this novel 3D vascular 
technique (13). The PESA 3DVUS methodology included evaluation of carotid and 
femoral arterial segments adjacent to the bifurcation in a standardized fashion. The 
protocol for the carotid arteries consisted of a 30o automatic sweep (explored vessel 
segment ≈6 cm long) centered at the carotid bulb to include the distal common carotid 
artery, the bulb, the bifurcation, and the proximal internal and external carotid artery 
segments. For the femoral arteries, the 30o and ≈6cm acquisition was centered at the 
bifurcation and included the mid-distal common femoral artery, the bifurcation, and the 
proximal superficial and deep femoral artery segments (Online Figure 1). The acquired 
images were analyzed off-line using the Vascular Plaque Quantification (VPQ) tool in 
QLAB 10.2 (Philips Health Care, Andover, MA, USA) at the Centro Nacional de 
Investigaciones Cardiovasculares (CNIC) Imaging Core Laboratory. For analysis, three 
contours were defined: the media-adventitia boundary, the lumen-intima boundary, and 
the plaque-lumen boundary (Online Figure 1). Ultrasound readers can then review and 
manually correct the contours that the software semi-automatically propagates throughout 
the imaged vessel. In this study, 3DVUS acquisitions were analyzed by four trained 
technicians blinded to other test results. There is currently no standard definition of 
atherosclerosis plaque using 3DVUS, and plaque was therefore defined using the 
Mannheim criteria for 2DVUS as a focal protrusion into the arterial lumen of thickness 
>0.5 mm or >50% of the IMT or IMT >1.5 mm (14). Plaque burden was quantified by 
measuring the volumes of all atherosclerotic plaques visualized within the standardized 
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6-cm acquisition. Global plaque burden was defined as the sum of plaque volumes in the 
right and left carotid and femoral arteries. We also recorded plaque presence (yes/no), the 
number of arteries affected, and the total number of plaques present in the 3DVUS 
acquisitions. Participants without plaques in the analyzed segment were assigned a plaque 
burden of 0 mm3. Plaque volume was not adjusted for artery size because we analyzed a 
fixed 6-cm segment regardless of total vessel size. 
Image quality was classified as “good” (diagnostic acoustic window without significant 
artifacts), “acceptable” (suboptimal window or artifacts but analysis could still be 
performed), and “inadequate” (reliable analysis not possible). Additionally, we identified 
specific features that may limit plaque analysis like “low-echodensity” (echogenicity 
similar to blood), “calcification” (causing significant acoustic shadowing), and “complex 
morphology” (highly irregular surface and possible surface defects).  
To assess the reproducibility of 3DVUS for plaque detection and volume measurement, 
a random sample of 32 participants was drawn from the entire study cohort, providing a 
total of 128 3DVUS studies (64 carotid and 64 femoral). Pairs of technicians analyzed all 
selected studies to evaluate interobserver agreement. To evaluate intraobserver 
agreement, the same reader repeated the initial analysis after 1 month. 
Statistical methods 
Baseline characteristics are presented as mean ± standard deviation or median and 
interquartile range (IQR) for continuous variables and counts and proportions for 
categorical variables. Differences between continuous variables and categorical variables 
were tested with unpaired t tests and chi-square tests, respectively. Variables with non-
normal distribution were log-transformed before comparison. For reproducibility 
analyses, intraclass correlation coefficient (ICC) and Bland-Altman plots were employed. 
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Kappa coefficients were used to assess agreement of plaque detection between 
techniques. For ICC and Kappa, good agreement was defined as >0.70 and excellent 
agreement as >0.90. 
Global plaque burden by 3DVUS is a right-skewed variable. The relationship between 
CVRFs and global plaque burden was explored by ordinal logistic regression, with plaque 
volume tertiles (outcome) used to classify atherosclerotic burden as none, mild, moderate, 
or severe. The candidate variables in the multivariable model were sex, age, smoking in 
pack-years, dyslipidemia, diabetes, hypertension, obesity, and family history of 
cardiovascular disease. To compare the effects of different CVRFs on plaque burden in 
our cohort we calculated the “adequacy” index (15). When excluding participants without 
plaques, linear regression on log-transformed plaque burden was used to investigate sex 
and age-related changes in the extent of carotid and femoral subclinical atherosclerosis. 
In addition, we used linear regression on log-transformed data to explore the association 
between global plaque burden and ASCVD risk score stratified by number of plaques and 
affected territories. A p for trend <0.05 was considered significant. Statistical analyses 
were conducted with Stata 12 (Stata Corp, College Station, TX). 
RESULTS 
The PESA cohort consists of 4184 participants. A total of 33 participants withdrew and 
167 were excluded due to incomplete 3DVUS studies in at least one of the 4 territories, 
resulting in 3984 participants available for analysis. A further 8 participants were 
excluded due to inadequate image quality in one or more territories and 116 were 
excluded due to missing information about CVRFs. The final study population thus 
comprised 3860 (92.2%) PESA participants (Figure 1). Baseline demographic, clinical, 
and laboratory characteristics are summarized in Table 1. In brief, there was a relatively 
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low prevalence of diabetes, hypertension, obesity, and family history of premature 
cardiovascular disease; in contrast, there was a non-negligible prevalence of dyslipidemia 
and cigarette smoking. Overall, the PESA participants are largely a low-risk population 
(median ASCVD risk 2.17% [IQR 0.95-4.37%]), with most (79.4%) in the low-risk 
category.  
A total of 15 936 arteries (99% of the 3DVUS studies) were successfully analyzed, with 
good image quality in 93% (Online Table 1). Acceptable quality window was slightly 
more frequent in the carotid territory than in the femoral territory (7.6% vs 6.2%). Low-
echogenic plaques (4.4%) or plaques with complex morphologies (2.3%) did not 
generally prevent adequate plaque volume analysis; and severe calcification was rare 
(0.03%). Interobserver and intraobserver agreement was good for the detection of plaque 
(kappa ranging from 0.87 to 0.97 and 0.94 to 1, respectively) and for global plaque burden 
quantification [ICC 0.89 (95%CI 0.86-0.91) and 0.87 (95%CI 0.83-0.90), respectively], 
with similar good results for carotid and femoral territories when analyzed separately 
(Online Tables 2 and 3). Bland-Altman plots for global and regional plaque volume 
quantification are shown in Online Figure 2. 
Sex, age, and territorial distribution of plaque burden by 3DVUS 
Plaque detection and plaque burden quantification by age, sex and territory is shown in 
Table 2. Median global plaque burden was 50.8 mm3 [IQR 18.7-121.5], being more 
pronounced in men than in women (63.4 mm3 [IQR 23.8-144.8] vs 25.7 mm3 [IQR 11.5-
61.6], p<0.001). For both sexes, plaque burden was higher in the femoral than the carotid 
territory (p<0.001) and increased significantly with age (Table 2). Men tended to have a 
higher age-related plaque burden increase for the femoral territory (Figure 2); 
nevertheless, this did not reach statistical significance when compared to the carotid 
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territory or to women (p=0.1 for both). Plaque burden values by percentiles are shown in 
Online Table 4, and percentile curves for each sex as a function of age are shown in Figure 
3. 
Similar results were observed for plaque presence (Table 2). Atherosclerosis was more 
prevalent in men (55.8%) than in women (30.5%). Overall, plaques were more frequent 
in the femoral than the carotid territory (32.1% vs 27.2%, p<0.001); however, while this 
remained true in men (42% vs 30.8%, p<0.001), the opposite was observed for women 
(15.1% vs 20.9%, p<0.001). 
Association of CVRFs and plaque burden 
The cardiovascular risk profile of participants without plaque and across tertiles of global 
plaque burden is showed in Table 3, and separately for carotid and femoral arteries in 
Online Tables 5 and 6. As expected, participants in the highest tertile were older and had 
a higher prevalence of all CVRFs except for family history of premature cardiovascular 
disease. The univariate and multivariate predictors of plaque burden are summarized in 
Table 4. Age, male sex, and all CVRFs demonstrated independent associations with 
plaque burden, but not family history and obesity. The strongest associations were noted 
for age, sex, and smoking exposure, followed by dyslipidemia, and hypertension, whereas 
diabetes was the weakest independent predictor in our cohort, and was not significant for 
carotid plaque burden. When comparing association of risk factors with either carotid or 
femoral plaque burden, the multivariate associations of age, male sex, smoking and 
dyslipidemia were stronger for the femoral than the carotid territory, while diabetes and 
hypertension showed no significant territorial differences. The magnitudes of these 
differences are shown in Figure 4. 
11 
 
Relationship between plaque volume versus plaque detection and cardiovascular 
risk scales  
Most participants were disease-free (53.6%). Involvement of 1, 2, 3, or 4 territories was 
noted in 22.9%, 14.2%, 5.6%, and 3.6% participants, and 1, 2, 3, or ≥4 plaques were 
detected in 19.8%, 11.6%, 6.3%, and 8.7% participants, respectively (Table 5 and Figure 
5; Central Illustration). Figures 5A and 5C display the distribution of disease presence 
across ASCVD risk categories. Plaque presence increased across risk categories whether 
assessed by the number of territories affected or the number of plaques. However, a non-
negligible proportion of participants classified at high-risk had only localized disease 
(19.1% and 15.4% of participants with 1 territory or plaque, respectively) and participants 
with extensive disease were found among the low-risk subgroup (1.8% and 4.6% of 
participants with 4 territories or ≥4 plaques). Detailed data on the number of plaques and 
affected territories as well as plaque burden across ASCVD risk categories are shown in 
Table 5. 
Global plaque burden showed a significant correlation with cardiovascular risk 
categories, and this relationship held after stratification by the number of affected 
territories (Figure 5B) or plaque number (Figure 5D). Plaque volume correlated 
significantly with higher cardiovascular risk category independently of the number of 
affected territories or the number of plaques, with a p trend <0.01 for all comparisons. 
DISCUSSION 
In the present study, we evaluated 3DVUS in a large population. We provide evidence 
that 3DVUS is a feasible and reproducible approach to not only detect but also quantify 
early atherosclerotic burden in the carotid and femoral arteries. In addition, we report the 
reference values of atherosclerotic plaque volume for a middle-aged, asymptomatic 
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population. The key messages derived from our observations are as follows: 1) Carotid 
and femoral 3DVUS identifies higher plaque burden in men, in the femoral arteries, and 
with increasing age; moreover, the pattern of disease changes with age is sex- and artery-
dependent; 2) 3DVUS-detected plaque burden is strongly associated with CVRFs, and 
this association is more significant for the femoral than for the carotid territory; 3) The 
evaluation of plaque burden in addition to plaque presence provides a closer match with 
global cardiovascular risk. 
Prevalence and distribution of plaque burden by 3DVUS 
A “pseudo-3DVUS” (freehand-2D-sweep/3D-like reconstruction) method was used 
previously for the carotid territory in the BioImage Study (10); however, the present study 
is the first study to evaluate carotid and femoral atherosclerosis with a true 3DVUS 
approach in a large cohort. In agreement with previous 2DVUS studies, we found that the 
plaque burden in men is almost double that in women within the middle-age range 
(16,17). However, we also found a higher plaque volume in the femoral territory in both 
sexes, whereas plaque presence was more frequent in the femoral arteries in men but in 
the carotid arteries in women. Furthermore, age-related changes in plaque volume tended 
to be more rapid in the femoral arteries in men. Thus, compared with plaque detection, 
plaque volume quantification unveils novel sex and artery-related differences in the early 
development of atherosclerotic disease. Prevalence of carotid atherosclerosis has been 
reported to be low in women before menopause (18,19), subsequently becoming similar 
to the prevalence in men (20). Our data suggest that the same pattern may occur with 
femoral atherosclerosis evaluated by 3DVUS. These observations are in accordance with 
the later development of cardiovascular disease in women until menopause worsens their 
cardiovascular risk profile. In addition, there is an increasing awareness of the importance 
of femoral artery evaluation for the detection of early subclinical atherosclerosis (7,8,21-
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23). Our results confirm that this territory is more extensively diseased in both sexes, 
suggesting a potential to improve early disease evaluation in the young. 
The availability of reference values in the population has been extremely valuable for 
image-based strategies for cardiovascular risk stratification. In the literature on CACS 
and carotid IMT, values above the 75th percentile are considered pathological in the 
general population (24,25). There are no previous reports on true 3DVUS-volumetric data 
in population-based cohorts, and this study provides a large dataset for future reference. 
Ongoing long-term PESA follow-up will help to identify associations with cardiovascular 
events. 
Relationship between plaque burden and CVRFs 
Many previous reports have associated CVRFs with carotid IMT and CACS (26,27). 
More recently, the Aragon Workers’ Heart Study (AWHS) assessed the association 
between CVRFs and carotid and femoral atherosclerosis in 1423 asymptomatic men 
between 40 and 59 years old (22). However, this study only evaluated the presence of 
plaque with 2DVUS and not its burden. Only a few groups have used quantitative 2DVUS 
measurements of peripheral atherosclerosis, like plaque area or plaque thickness, in the 
general population (28,29). Our study confirms the strong association between multiple 
CVRFs and atherosclerotic plaque burden as measured with 3DVUS. Age was the 
strongest predictor of plaque burden, followed by sex and the modifiable risk factors, as 
demonstrated by the adequacy index. Among the modifiable risk factors, smoking 
exposure in pack-years was strongly associated with atheroma burden, followed by 
dyslipidemia, hypertension and, to a lesser extent, diabetes. Although this is in apparent 
contradiction with the well-documented relation between diabetes and increased 
atherosclerosis, it probably reflects the low prevalence of diabetes in our cohort and the 
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likely short disease exposure among those who are affected. In a further analysis (data 
not shown), being a smoker also showed an independent association with plaque burden 
(Adequacy index = 0.16 p<0.001). However, pack-years of smoking was more strongly 
related than the simple smoking status to baseline plaque burden. Contrasting with our 
results, AWHS did not find dyslipidemia and diabetes to be significant predictors of the 
presence of carotid plaques even though these risk factors were more prevalent than in 
our study, highlighting the difference between simple plaque detection versus burden 
quantification. In this regard, Yerly et al. evaluated the link between CVRFs and 2DVUS-
quantified carotid and femoral atherosclerosis in a middle-aged cohort (n=496, age 45-64 
years) (29). CVRFs were more strongly associated with quantitative plaque measures than 
IMT. Notably, the relationship between CVRFs and carotid plaque thickness was 
inconsistent and become clearer when plaque area was measured. The authors attributed 
this to high variability in 2DVUS measurements, something that 3DVUS has partially 
overcome (30). Together, the results of these studies and ours suggest that more 
comprehensive measures of atherosclerotic burden such as plaque volume may better 
reflect long-term CVRF exposure.  
Territorial differences in the relationship between plaque burden and CVRFs 
Beyond the age- and sex-based differences discussed above, the associations between 
CVRFs and plaque burden tended to be stronger for the femoral than the carotid territory. 
Similar observations were reported in AWHS (22) and by Yerly et al. (29), both using 
2DVUS, although these studies did not make formal comparisons. Our analyses confirm 
these observations, showing statistical significant differences for sex, age, smoking, and 
dyslipidemia. Smoking has been linked to peripheral artery disease and intermittent 
claudication (31), and early atherosclerotic changes are more significant in the femoral 
compared to the carotid territory in patients with familial hypercholesterolemia (32). The 
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apparent lack of territorial differences in hypertension contrasts with previous reports that 
have tended to link high blood pressure with carotid atherosclerosis and stroke (16,33). 
However, these studies did not include assessment of the femoral territory and usually 
enrolled older populations. In accordance with our results, the few available reports in 
middle-aged participants show a relationship between hypertension and both carotid and 
femoral subclinical atherosclerosis (22,29,34). The mechanisms of these artery-related 
differences are unclear, and are likely related to both histological and hemodynamic 
factors (35). Overall, our findings support multi-territorial imaging for comprehensive 
evaluation of subclinical atherosclerosis and the combined effect of CVRFs in early 
atheroma formation. 
Relationship of plaque volume and plaque presence with cardiovascular risk 
Our results confirm the well-established mismatch between cardiovascular risk profile 
determined by risk scales and the presence of subclinical atherosclerosis (7,36), which 
has been attributed to variable individual susceptibility. However, adding plaque burden 
quantification to the detection of plaque presence provides a clearer picture of the 
relationship between risk and subclinical disease: among individuals with the same 
number of plaques or affected territories, global plaque burden was independently and 
positively associated with estimated ASCVD risk. Global plaque volume, by integrating 
plaque presence, number, and plaque size, is a more comprehensive index of disease 
burden that may better reflect individual susceptibility, and thus partially explain the 
mismatch between risk profile and plaque presence. The difference between disease 
presence and volume is also illustrated by the discrepancy between these two methods in 
comparing disease severity between the femoral and carotid arteries in women; the 
number of plaques was similar or even lower in the femoral territory, but femoral plaque 
volume was almost double that in the carotid territory. The potential of plaque burden 
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quantification to improve cardiovascular risk stratification is suggested by the BioImage 
study, which showed that quantifying carotid burden as the sum of consecutive plaque 
areas in mm2 improves risk prediction, risk reclassification, and statin eligibility for 
primary prevention strategies with comparable results to CACS (37,38). Also, previous 
studies using 2D plaque area measurements demonstrated significant improvement in risk 
prediction of myocardial infarction, stroke, and even cardiovascular death (39-41). Our 
results suggest that the ability of global plaque burden to predict cardiovascular risk is 
likely to be improved by adding evaluation of the femoral arteries at early stages of 
cardiovascular disease. 
Feasibility and reproducibility of 3DVUS PESA protocol 
Assessment of the 3DVUS method in PESA demonstrated good feasibility for screening 
early atherosclerosis, providing a unique opportunity to study subclinical disease in large 
populations. Previous 3DVUS approaches reported drop-out rates that varied depending 
on the clinical context, ranging from 23% in patients undergoing revascularization of 
peripheral artery disease (42) to 33% in patients with recent ischemic stroke or transient 
ischemic attack (43). The main reported cause of dropout in these studies was a high 
percentage of severely calcified plaques, suggesting that 3DVUS performs worse at 
advanced stages of atherosclerosis compared with our sample of individuals in the early 
stages of disease. Also, the 3DVUS protocol developed in PESA, by centering the 
acquisition at bifurcations without probe displacement, is simple and has good 
reproducibility, ensuring the re-evaluation of the same segment during follow-up to detect 






This is a cross-sectional study and so does not allow causal inference about the 
relationships between CVRFs and plaque volume. Similarly, whether 3DVUS plaque 
volume is associated with increased number of events is currently unknown, and we can 
only infer a potential role to predict cardiovascular risk. Future follow-up data from the 
PESA cohort will help confirm this hypothesis by evaluating associations with 
cardiovascular outcomes. Finally, our sample represents a middle-aged, white-collar 
working population, which may limit the generalizability of the results, and our findings 
need further validation in other cohorts.  
CONCLUSIONS 
3DVUS is a feasible, reproducible and novel imaging technique for quantifying early 
carotid and femoral atherosclerotic burden in large populations. Quantitative plaque 
burden, especially in the femoral arteries, is associated with conventional CVRFs. 
Additionally, 3DVUS offers incremental value over the presence of plaque alone in its 
association with cardiovascular risk. This inexpensive and radiation-free technology thus 
has the potential to become a key large-scale screening tool for identifying at-risk 
individuals.   
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CORE CLINICAL COMPETENCIES: Atherosclerosis is the leading cause of death 
and disability worldwide, and the introduction of effective strategies for primary 
prevention is a healthcare priority. Atherosclerosis burden quantification by carotid and 
femoral 3DVUS has potential as a primary measure of individual cardiovascular risk, 
complementing scales based on traditional risk factors and improving previous 2DVUS-
based atherosclerotic risk markers. In addition, the standardized 3DVUS PESA protocol 
for carotid and femoral plaque burden quantification is a feasible and reliable imaging 
method for screening the general population.  
TRANSLATIONAL OUTLOOK IMPLICATIONS: Extending the use of imaging 
techniques to the general population requires a technique that is simple, reliable and cost-
effective. 3DVUS using the volumetric-linear array method is valid for imaging 
superficial peripheral atherosclerosis burden from early to advanced stages. 3DVUS has 
the potential to become a key population screening tool for identifying at-risk individuals, 
targeting preventive therapy or monitoring the response to treatment. Moreover, this 
bedside method is simple and radiation-free, encouraging its uptake in clinical practice 
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FIGURE TITLES AND CAPTURES 
Figure 1. Flow diagram on the 3DVUS study population  
Figure 2. Distribution of femoral and carotid atherosclerotic plaque volume by sex 
and age 
Box-plots represent median and interquartile range, and dots represent the outlier values 
of femoral and carotid plaque burden in mm3 across age categories in those participants 
with evidence of atherosclerotic disease (i.e. excluding participants with a plaque 
burden of 0 mm3). The p values for trend of the age-related increases in carotid and 
femoral plaque burden are shown.  
Figure 3. Percentiles of global plaque burden stratified by age and sex  
Each plot shows the curves for the percentiles of global plaque burden in mm3 across 
age in the study cohort, including healthy participants (plaque burden of 0 mm3) and 
diseased participants. Disease appears later in women than in men, and plaque burden in 
men is strikingly higher than in women of the same age. 
Figure 4. Multivariable analysis for the prediction of carotid and femoral 
atherosclerotic plaque burden 
Smoking, dyslipidemia, diabetes and hypertension were predictors of atherosclerotic 
plaque burden after adjustment for sex, age, and all evaluated CVRFs. The strength of 
the relationship between sex, age, and CVRFs tends to be higher in the femoral 
territory, except for hypertension. 
95% CI: 95% confidence interval. CV: cardiovascular. PB: plaque burden. 
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CENTRAL ILUSTRATION Figure 5. Relationship between global plaque burden 
and the estimated cardiovascular risk stratified by plaque presence-based 
atherosclerosis markers  
A and C show the distribution of disease among ASCVD risk categories stratified by the 
number of territories affected and the number of plaques (excluding no disease). B and D 
show mean global plaque burden across risk strata adjusted by the number of territories 
affected and number of plaques. The p values for the trend between plaque burden and 




Table 1. Characteristics of the study population  
 
  Total (n=3860) Men (n=2434) Women (n=1426) p value 
 
Age (years) 45.8 ± 4.3 46.2 ± 4.4 45.0 ± 3.9 <0.001 
CV risk factors 
Dyslipidemia 1600 (41.5) 1303 (53.5) 297 (20.8) <0.001 
Diabetes 71 (1.8) 64 (2.6) 7 (0.5) <0.001 
Hypertension 447 (11.6) 378 (15.5) 69 (4.8) <0.001 
Smoking  794 (20.6) 467 (19.2) 327 (22.9) 0.005 
Pack-years of smoking 14.5 [7.2-24.3] 15.8 [7.4-26.6] 13.0 [7.1-26.2] 0.182 
Obesity 573 (14.8) 470 (19.3) 103 (7.2) <0.001 
Family history of CV disease 600 (15.5) 370 (15.2) 230 (16.1) 0.443 
CV risk factors therapy 
Lipid-lowering   270 (7.0)   225 (9.2)    45 (3.2) <0.001 
Antihypertensive   287 (7.4)   246 (10.1)    41 (2.9) <0.001 
Antidiabetic   54 (1.4)   48 (2.0)    6 (0.4) <0.001 
Number of CV risk factors 
  0 1699 (44) 840 (34.5) 859 (60.2) <0.001 
  1 1506 (39) 1060 (43.5) 446 (31.3) <0.001 
  2 564 (14.6) 454 (18.7) 110 (7.7) <0.001 
>2 91 (2.4) 80 (3.3) 11 (0.8) <0.001 
Conventional risk scales 
10-year ASCVD risk* 2.17 [0.95 – 4.37] 3.40 [1.92 – 5.77] 0.79 [0.44 – 1.59] <0.001 
Categorical variables are presented as n (%) and quantitative variables as mean ± SD or median [interquartile range; 





Table 2. Prevalence of atherosclerosis and plaque burden distribution by 3DVUS  
  TOTAL (n=3860) MEN (n=2434) WOMEN (n=1426) *p value 
GLOBAL PLAQUE 
BURDEN N (%)  Median (IQR) N (%)  Median (IQR) N (%)  Median (IQR) N Median 
All 1792 (46.4) 50.8 [18.7 – 121.5] 1357 (55.8) 63.4 [23.8 – 144.8] 435 (30.5) 25.7 [11.5 – 61.6] <0.001 <0.001 
40-44 yo 584 (34.5) 31.2 [12.7 – 78.2] 421 (43.4) 42.0 [16.3 – 99.3] 163 (22.5) 16.8 [9.1 – 37.7] <0.001 <0.001 
45-49 yo 612 (47.6) 55.0 [19.7 -121.2] 445 (55.5) 66.7 [24.3 – 144.8] 167 (34.4) 30.0 [14.4 – 72.8] <0.001 <0.001 
50-54 yo 596 (67.9) 78.9 [27.7 -176.6] 491 (74.3) 86.2 [32.1 – 207.6] 105 (48.4) 38.6 [16.0 – 89.3] <0.001 <0.001 
†p value  <0.001 <0.001 <0.001 <0.001 <0.001 <0.001   
CAROTID PLAQUE 
BURDEN             
 
All 1048 (27.2) 23.1 [9.9 – 48.7] 750 (30.8) 25.5 [11.4 – 54.9] 298 (20.9) 16.3 [7.6 – 33.6] <0.001 <0.001 
40-44 yo 342 (20.2) 17.9 [8.2 – 37.3] 225 (23.2) 20.5 [9.3 – 43.4] 117 (16.2) 13.2 [6.9 – 25.1] 0.001 <0.001 
45-49 yo 338 (26.3) 22.6 [10.3 – 50.2] 234 (29.2) 25.2 [12.1 – 55.0] 104 (21.4) 17.3 [7.7 – 38.8] 0.002 0.019 
50-54 yo 368 (41.9) 28.7 [12.7 – 58.1] 291 (44.0) 29.7 [13.6 – 64.1] 77 (35.5) 23.1 [9.9 – 46.4] 0.027 0.065 
†p value <0.001 <0.001 <0.001 0.002 <0.001 <0.001   
FEMORAL PLAQUE 
BURDEN             
 
All 1238 (32.1) 64.0 [27.6 – 140.5] 1023 (42.0) 72.5 [30.8 – 157.1] 215 (15.1) 36.7 [18.2 –78.7] <0.001 <0.001 
40-44 yo 331 (19.5) 48.2 [23.8 – 107.5] 271 (27.9) 56.7 [26.8 – 118.4] 60 (8.3) 28.2 [15.0 – 45.2] <0.001 <0.001 
45-49 yo 441 (34.3) 63.3 [25.9 – 131.2] 346 (43.1) 67.6 [30.9 – 151.2] 95 (19.6) 36.7 [17.9 – 90.5] <0.001 <0.001 
50-54 yo 466 (53.1) 82.2 [35.2 – 177.0] 406 (61.4) 86.0 [37.8 –194.2] 60 (27.6) 47.2 [19.9 – 95.8] <0.001 <0.001 
†p value <0.001 <0.001 <0.001 <0.001 <0.001 0.018   
‡p value <0.001 <0.001 <0.001 <0.001 <0.001 <0.001   
*p value of the differences between men and women. †p value of the differences among age strata. ‡ p value of the differences between carotid and femoral territory. 
Plaque volume data only include participants with plaques (values of 0mm3 were excluded for the calculation). 
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Table 3. Participant’s characteristics according to global plaque burden tertiles 
 
 


















Age (years) 44.6 ± 3.9 45.8 ± 4.3 46.9 ± 4.3 48.3 ± 4.1 <0.001 
Sex (male) 991 (47.9) 221 (37.2) 146 (24.5) 68 (11.3) <0.001 
CV risk factors  
Dyslipidemia 648 (31.3) 258 (43.4) 310 (52) 384 (63.8) <0.001 
Diabetes 17 (0.8) 8 (1.4) 16 (2.7) 30 (5) <0.001 
Hypertension 153 (7.4) 60 (10.1) 94 (15.8) 140 (23.3) <0.001 
Smoking  298 (14.4) 123 (20.7) 150 (25.2) 223 (37) <0.001 
Pack-years of smoking 9.2 [5.1-16.8] 13.0 [7.0-21.7] 17.3 [9.5-25.0] 22.8 [11.6-32.5] <0.001 
Obesity 251 (12.1) 77 (13) 119 (20) 126 (20.9) <0.001 
Family history of CV disease 308 (14.9) 94 (15.8) 96 (16.1) 102 (16.9) 0.191 
CV risk factors therapy  
Lipid-lowering 74 (3.6) 34 (5.7) 70 (11.7) 92 (15.3) <0.001 
Antihypertensive 87 (4.2) 42 (7.1) 58 (9.7) 100 (16.6) <0.001 
Antidiabetic 14 (0.7) 8 (1.4) 12 (2) 20 (3.3) <0.001 
Number of CV risk factors          
  0 1144 (55.3) 254 (42.8) 183 (30.7) 118 (19.6) <0.001 
  1 741 (35.8) 240 (40.4) 278 (46.6) 247 (41) <0.001 
  2 174 (8.4) 91 (15.3) 114 (19.1) 185 (30.7) <0.001 
>2 9 (0.4) 9 (1.5) 21 (3.5) 52 (8.6) <0.001 
Conventional risk scales          
10-year ASCVD risk 1.44 [0.65 - 2.87] 2.16 [1.07 – 4.04] 3.38 [1.71 – 5.55] 5.05 [2.92 – 8.19] <0.001 





Table 4. Univariate and multivariate predictors of global, carotid, and femoral plaque burden 
 *Univariate Proportional Odds      
 Global Plaque Burden Carotid Plaque Burden Femoral Plaque Burden  
 OR (95% CI) p  value OR (95% CI) p  value OR (95% CI) p  value ‡ p value 
Sex (male) 3.19 (2.79 to 3.65) <0.001 1.76 (1.51 to 2.05) <0.001 4.28 (3.63 to 5.05) <0.001 <0.001 
Age (5 years) 2.07 (1.92 to 2.22) <0.001 1.73 (1.59 to 1.88) <0.001 2.19 (2.02 to 2.38) <0.001 <0.001 
Smoking  2.43 (2.10 to 2.81) <0.001 1.83 (1.56 to 2.16) <0.001 2.59 (2.22 to 3.01) <0.001 0.003 
Smoking (10 pack-years) 1.77 (1.65 to 1.90) <0.001 1.45 (1.35 to 1.55) <0.001 1.76 (1.64 to 1.89) <0.001 <0.001 
Dyslipidemia 2.60 (2.30 to 2.94) <0.001 1.86 (1.61 to 2.14) <0.001 2.97 (2.59 to 3.40) <0.001 <0.001 
Diabetes 4.06 (2.63 to 6.25) <0.001 2.80 (1.78 to 4.41) <0.001 4.34 (2.85 to 6.60) <0.001 0.181 
Hypertension 2.69 (2.24 to 3.23) <0.001 2.15 (1.76 to 2.62) <0.001 2.69 (2.23 to 3.24) <0.001 0.129 
Family history of CV disease 1.12 (0.95 to 1.31) 0.191 1.12 (0.93 to 1.36) 0.242 1.16 (0.97 to 1.39) 0.102 0.796 
Obesity 1.67 (1.41 to 1.97) <0.001 1.43 (1.19 to 1.72) <0.001 1.81 (1.52 to 2.16) <0.001 0.074 
 †Multivariate Proportional Odds       
 OR (95% CI) AI p  value OR (95% CI) p  value OR (95% CI) p  value ‡ p value 
Sex (male) 2.63 (2.27 to 3.04) 0.32 <0.001 1.38 (1.17 to 1.62) <0.001 3.55 (2.97 to 4.26) <0.001 <0.001 
Age (5 years) 1.79 (1.66 to 1.93) 0.41 <0.001 1.53 (1.40 to 1.67) <0.001 1.87 (1.71 to 2.03) <0.001 <0.001 
Smoking (10 pack-years) 1.75 (1.62 to 1.88) 0.28 <0.001 1.36 (1.26 to 1.46) <0.001 1.73 (1.60 to 1.87) <0.001 <0.001 
Dyslipidemia 1.55 (1.35 to 1.77) 0.24 <0.001 1.33 (1.14 to 1.55) <0.001 1.68 (1.44 to 1.95) <0.001 <0.001 
Diabetes 1.91 (1.21 to 3.02) 0.04 0.006 1.58 (0.98 to 2.53) 0.059 1.84 (1.17 to 2.89) 0.008 0.185 
Hypertension 1.47 (1.21 to 1.80) 0.12 <0.001 1.44 (1.16 to 1.78) <0.001 1.39 (1.13 to 1.71) 0.002 0.116 
Family history of CV disease 1.05 (0.88 to 1.25) 0.00 0.621 1.05 (0.87 to 1.28) 0.605 1.09 (0.90 to 1.32) 0.395 0.744 
Obesity 0.98 (0.82 to 1.18) 0.04 0.843 1.01 (0.82 to 1.23) 0.961 1.03 (0.85 to 1.24) 0.798 0.060 
AI: adequacy index. CI: confidence interval. CV: cardiovascular. OR: odds ratio.  
*Unadjusted odds ratios for conventional cardiovascular risk factors (CVRF). †Adjusted model by sex, age, and CVRFs (pack-years of smoking, dyslipidemia, diabetes, hypertension, 
family history of CV disease, and obesity). 
‡ p value of the difference between carotid and femoral OR. 
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Table 5. Relationship with ASCVD risk of the number of affected territories, the total number of plaques, and plaque burden  
 
     10-year ASCVD risk 
 
TOTAL LOW 
ASCVD <5% (n=3066) 
INTERMEDIATE 
ASCVD 5-7.5% (n=423) 
HIGH 
ASCVD ≥7.5% (n=371) *p value  
 TERRITORIES AFFECTED N (%) N (%) Median [IQR] mm3 N (%) Median [IQR] mm3 N (%) Median [IQR] mm3 Median (mm3) 
   NO PLAQUE  2068 (53.6) 1869 (60.9) 0 127 (30.02) 0 72 (19.4) 0 - 
   1 TERRITORY  886 (22.9) 698 (22.7) 18.8 [9.1-40.1] 117 (27.6) 27.7 [11.8-49.6] 71 (19.1) 27.5 [12.0-55.4] <0.001 
   2 TERRITORIES  549 (14.2) 346 (11.2) 76.9 [35.6-121.1] 105 (24.8) 88.4 [49.7-158.5] 98 (26.4) 119.2 [56.6-188.3] <0.001 
   3 TERRITORIES  217 (5.6) 97 (3.1) 131.9 [74.7-206.0] 48 (11.3) 162.9 [89.5-248.5]  72 (19.4) 185.3 [92.9-274.5] 0.005 
   4 TERRITORIES  140 (3.6) 56 (1.8) 246.5 [125.1-352.8] 26 (6.1) 260.7 [182.9-359.8] 58 (15.6) 310.2 [195.5-510.2] 0.014 
     10-year ASCVD risk 
    LOW 
ASCVD <5% (n=3066) 
INTERMEDIATE 
ASCVD 5-7.5% (n=423) 
HIGH 
ASCVD ≥7.5% (n=371) *p value 
 NUMBER OF PLAQUES N (%) N (%) Median [IQR] mm3 N (%) Median [IQR] mm3 N (%) Median [IQR] mm3 Median (mm3) 
NO PLAQUE  2068 (53.6) 1869 (61.0) 0 127 (30.0) 0 72 (19.4) 0 - 
1 PLAQUE  763 (19.8) 606 (19.8) 17.6 [8.7 – 36.7] 100 (23.6) 27.1 [11.1 – 47.3] 57 (15.4) 25.7 [9.7 – 46.2] 0.001 
2 PLAQUES  450 (11.6) 301 (9.8) 49.3 [24.0 – 95.6] 82 (19.6) 67.6 [37.2 – 153.7] 66 (17.8) 64.7 [33.7 – 130.9] <0.001 
3 PLAQUES  242 (6.3) 149 (4.9) 89.8 [51.0 – 146.2] 44 (10.4) 112.2 [74.7 – 177.2] 49 (13.2) 121.3 [73.5 – 216.7] <0.001 
≥4 PLAQUES  337 (8.7) 141 (4.6) 156.3 [84.5 – 262.7] 69 (16.3) 183.6 [92.3 – 304.4] 127 (34.2) 238.5 [150.5 – 376.2] <0.001 
 ASCVD: atherosclerosis cardiovascular disease. IQR: interquartile range. 
*p of trend in the association between disease burden and estimated ASCVD risk 
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Figure 2. Distribution of femoral and carotid atherosclerotic plaque volume by sex and age 
Box-plots represent median and interquartile range, and dots represent the outlier values of femoral and 
carotid plaque burden in mm3 across age categories in those participants with evidence of atherosclerotic 
disease (i.e. excluding participants with a plaque burden of 0 mm3). The p values for trend of the age-related 









Figure 3. Percentiles of global plaque burden stratified by age and sex  
Each plot shows the curves for the percentiles of global plaque burden in mm3 across age in the study cohort, including healthy participants (plaque burden of 0 





Figure 4. Multivariable analysis for the prediction of carotid and femoral atherosclerotic plaque 
burden 
Smoking, dyslipidemia, diabetes and hypertension were predictors of atherosclerotic plaque burden after 
adjustment for sex, age, and all evaluated CVRFs. The strength of the relationship between sex, age, and 
CVRFs tends to be higher in the femoral territory, except for hypertension. 







CENTRAL ILUSTRATION Figure 5. Relationship between global plaque burden and the estimated 
cardiovascular risk stratified by plaque presence-based atherosclerosis markers  
A and C show the distribution of disease among ASCVD risk categories stratified by the number of 
territories affected and the number of plaques (excluding no disease). B and D show mean global plaque 
burden across risk strata adjusted by the number of territories affected and number of plaques. The p values 







Online table 1. Feasibility analysis of 3DVUS in the PESA cohort 
 
 3DVUS 
 Feasibility analysis in PESA cohort Total Carotid Femoral 
Missing 3DVUS studies 167 35 136 
Nº arteries analyzed  15 936  7968 7968 
Nº arteries with atherosclerosis  3293 (20.6%) 1416 (17.7%) 1877 (23.5%) 
Echo quality:     
          Good  14 821 (93.0%) 7355 (92.3%) 7466 (93.6%) 
          Acceptable 1108 (6.9%) 610 (7.6%) 498 (6.2%) 
          Inadequate  7 (0.04%) 3 (0.04%) 4 (0.05%) 
Limiting plaque features:     
         Low-echogenic plaques  145 (4.4%) 35 (2.4%) 110 (5.8%) 
         Sever calcification with echo-shadows 1 (0.03%) 0 1 (0.05%) 






Online Table 2. Kappa values for agreement in plaque detection with 3DVUS  
Interoserver and intraobserver kappa coefficients. 
 
Interobserver Kappa for plaque detection on 3DVUS  
n=69 All territories Carotid territory Femoral territory 
 Observer 2 Observer 3 Observer 2 Observer 3 Observer 2 Observer 3 
Observer 1 0.95 0.89 0.94 0.84 0.97 0.93 
Observer 2  0.87  0.84  0.90 
Intraobserver Kappa for plaque detection on 3DVUS 
 All territories Carotid territory Femoral territory 
Observer 1 1 1 1 
Observer 2 1 1 1 







Online Table 3. Reproducibility of 3DVUS atherosclerotic plaque volume measurement in all territories and in carotid and femoral arteries separately 
Interobserver and intraobserver intraclass correlation coefficient (ICC) and 95% confidence interval. 
 
Interobserver ICC for 3DVUS Volume measurement  
All territories Carotid territory Femoral territory 
n=69 Observer 2 Observer 3 Observer 2 Observer 3 Observer 2 Observer 3 
Observer 1 0.81 (0.70-0.88) 0.85 (0.77-0.91) 0.89 (0.76-0.95) 0.80 (0.58-0.91) 0.77 (0.59-0.87) 0.83 (0.70-0.91) 
Observer 2  0.86 (0.77-0.91)  0.76 (0.54-0.88)  0.85 (0.93-0.92) 
Global 0.89 (0.86-0.91) 0.81 (0.67-0.91) 0.82 (0.71-0.89) 
Intraobserver ICC for 3DVUS Volume measurement  
n=69 All territories Carotid territory Femoral territory 
Observer 1 0.97 (0.94-0.98) 0.90 (0.77-0.95) 0.97 (0.95-0.99) 
Observer 2 0.96 (0.94-0.98) 0.96 (0.91-0.98) 0.95 (0.91-0.97) 
Observer 3 0.88 (0.81-0.93) 0.88 (0.76-0.94) 0.85 (0.73-0.92) 




Online Table 4. Percentiles of global, carotid, and femoral plaque burden by age and sex  
 
 GLOBAL PLAQUE BURDEN (mm3)  CAROTID PLAQUE BURDEN (mm3)  FEMORAL PLAQUE BURDEN (mm3) 
 Men  Women   Men  Women   Men  Women  
Age 40-45 45-50 50-55 40-45 45-50 50-55 Age 40-45 45-50 50-55 40-45 45-50 50-55 Age 40-45 45-50 50-55 40-45 45-50 50-55 
n 971 802 661 724 485 217 n 971 802 661 724 485 217 n 971 802 661 724 485 217 
p5th 0 0 0 0 0 0 p5th 0 0 0 0 0 0 p5th 0 0 0 0 0 0 
p10th 0 0 0 0 0 0 p10th 0 0 0 0 0 0 p10th 0 0 0 0 0 0 
p25th 0 0 0 0 0 0 p25th 0 0 0 0 0 0 p25th 0 0 0 0 0 0 
p50th 0 9.9 45.3 0 0 0 p50th 0 0 0 0 0 0 p50th 0 0 28.4 0 0 0 
p75th 31.0 75.2 147.4 0 16.3 34.4 p75th 0 7.6 25.5 0 0 11.2 p75th 12.6 58.4 128.1 0 0 11.9 
p90th 106.3 200.4 304.4 21.5 62.6 116.7 p90th 25.0 39.3 69.7 9.6 19.4 45.5 p90th 89.7 163.5 260.6 0 36.3 74.3 


























Age (years) 45.2 ± 4.1 46.3 ± 4.5 47.3 ± 4.3 47.9 ± 4.2 <0.001 
Sex (male) 1128 (40.1) 126 (36.3) 102 (29.3) 70 (19.9) <0.001 
CV risk factors  
Dyslipidemia 1054 (37.5) 164 (47.3) 172 (49.3) 210 (59.7) <0.001 
Diabetes 37 (1.3) 8 (2.3) 7 (2) 19 (5.4) <0.001 
Hypertension 266 (9.5) 42 (12.1) 54 (15.5) 85 (24.1) <0.001 
Smoking 501 (17.8) 86 (24.8) 88 (25.2) 119 (33.8) <0.001 
Pack-years of smoking 12.0 [6.2-21.0] 14.7 [7.7-25.2] 17.7 [8.8-31.0] 22.5 [10.5-32.4] <0.001 
Obesity 383 (13.6) 55 (15.9) 63 (18.1) 72 (20.5) <0.001 
Family history of CV disease 428 (15.2) 43 (12.4) 70 (20.1) 59 (16.8)  0.242 
CV risk factors therapy  
Lipid-lowering 154 (5.5) 32 (9.2) 34 (9.7) 50 (14.2) <0.001 
Antihypertensive 163 (5.8) 29 (8.4) 36 (10.3) 59 (16.8) <0.001 
Antidiabetic 29 (1) 7 (2) 6 (1.7) 12 (3.4)  0.001 
Number of CV risk factors          
  0 1,364 (48.5) 128 (36.9) 123 (35.2) 84 (23.9) <0.001 
  1 1,072 (38.1) 147 (42.4) 143 (41) 144 (40.9)  0.077 
  2 342 (12.2) 64 (18.4) 72 (20.6) 86 (24.4) <0.001 
>2 34 (1.2) 8 (2.3) 11 (3.2) 38 (10.8) <0.001 
Conventional risk scales          
10-year ASCVD risk 1.88 [0.84 - 3.72] 2.41 [1.09 – 5.06] 3.19 [1.55 – 5.80] 4.19 [2.46 – 7.63] <0.001 































Age (years) 44.9 ± 4.0 46.7 ± 4.4 47.6 ± 4.1 48.5 ± 4.1 <0.001 
Sex (male)   1211 (46.2)   110 (26.8)   72 (17.4)   33 (7.9) <0.001 
CV risk factors  
Dyslipidemia 863 (32.9) 229 (55.9) 237 (57.4) 271 (65.3) <0.001 
Diabetes 22 (0.8) 11 (2.7) 16 (3.9) 22 (5.3) <0.001 
Hypertension 214 (8.2) 57 (13.9) 76 (18.4) 100 (24.1) <0.001 
Smoking 403 (15.4) 108 (26.3) 122 (29.5) 161 (38.8) <0.001 
Pack-years of smoking 9.9 [5.2-18.0] 16.6 [9.7-25.4] 18.0 [10.5-28.0] 24.0 [11.7-33.0] <0.001 
Obesity 323 (12.3) 65 (15.9) 96 (23.2) 89 (21.4) <0.001 
Family history of CV disease 392 (15) 65 (15.9) 68 (16.5) 75 (18.1)  0.102 
CV risk factors therapy  
Lipid-lowering 102 (3.9) 46 (11.2) 59 (14.3) 63 (15.2) <0.001 
Antihypertensive 125 (4.8) 37 (9) 54 (13.1) 71 (17.1) <0.001 
Antidiabetic 19 (0.7) 10 (2.4) 11 (2.7) 14 (3.4) <0.001 
Number of CV risk factors          
  0 1397 (53.3) 122 (29.8) 107 (25.9) 73 (17.6) <0.001 
  1 965 (36.8) 182 (44.4) 188 (45.5) 171 (41.2) <0.001 
  2 243 (9.3) 96 (23.4) 93 (22.5) 132 (31.8) <0.001 
>2 17 (0.6) 10 (2.4) 25 (6.1) 39 (9.4) <0.001 
Conventional risk scales          
10-year ASCVD risk 1.56 [0.71-3.11] 3.14 [1.71 – 5.29] 4.03 [2.26 – 6.22] 5.46 [3.30 – 9.01] <0.001 







Online Figure 1. 3DVUS atherosclerosis assessment 
(A) 3D automatic sweep acquisition of a subclinical atherosclerotic plaque in the left femoral artery. Panels 
2, 3, and 4 show the X, Y, and Z axis views of the vessel, and panel 1 shows the reconstructed 3D volume 
image in an axial view of the distal common femoral artery. (B) Semiautomatic delineation of consecutive 
axial views of the atherosclerotic plaque: calculated atherosclerotic volume, 92.47 mm3; maximum plaque 
thickness, 1.7 mm; and maximum percentage stenosis, 10%. The yellow line marks the intima-lumen 





Online Figure 2. Reproducibility of 3DVUS evaluation of global, carotid, and femoral atherosclerotic 
plaque burden 
Bland-Altman plots for interobserver and intraobserver agreement between the three readers for global 
atherosclerotic plaque volume quantification (A and B) and interobserver agreement separately for carotid and 
femoral arteries (C and D). 
Legends: +2SD: superior limit of agreement. -2SD: inferior limit of agreement. OBS1: observer 1. 
 
 
 
 
 
